Log in
Inhaled analgesic (volatile anesthetic)

Methoxyflurane

Methoxyflurane is a halogenated ether volatile anesthetic agent used at sub-anesthetic doses as an inhaled analgesic for acute pain relief. Initially developed as a general anesthetic in the 1960s, its anesthetic use was discontinued due to dose-dependent nephrotoxicity from fluoride metabolites. At low analgesic doses (3-6 mL via handheld inhaler), methoxyflurane provides rapid-onset pain relief for trauma, procedures, and acute pain with a much lower nephrotoxicity risk.

Practice questionsHigh-yield facts
Drug classInhaled analgesic, halogenated volatile ether
MechanismCNS depression via GABA-A agonism and NMDA antagonism
Main usesAcute trauma pain, procedural analgesia in emergency settings
Key adverse effectDose-dependent nephrotoxicity from fluoride ion metabolites
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Methoxyflurane produces analgesia and anesthesia through multiple mechanisms involving central nervous system depression:

  • GABA-A receptor potentiation: Enhances inhibitory neurotransmission by increasing chloride channel opening, leading to neuronal hyperpolarization
  • NMDA receptor antagonism: Blocks glutamatergic excitatory neurotransmission, contributing to analgesia and dissociative effects
  • Two-pore domain potassium channel activation: Hyperpolarizes neurons and reduces excitability
  • Glycine receptor modulation: Additional inhibitory effects in the spinal cord

At sub-anesthetic concentrations used for analgesia (0.1-0.3% inspired concentration), methoxyflurane primarily provides pain relief without loss of consciousness. The MAC (minimum alveolar concentration) for anesthesia is 0.16%, but analgesic use targets concentrations well below this threshold.

Methoxyflurane is metabolized extensively by hepatic cytochrome P450 enzymes (primarily CYP2E1) to inorganic fluoride ions and other metabolites. The fluoride ions are responsible for the dose-dependent renal toxicity that limited its use as a general anesthetic.

High-yield for exams
  • Methoxyflurane causes dose-dependent nephrotoxicity from fluoride metabolites; peak fluoride >50 μmol/L causes high-output renal failure
  • Withdrawn as general anesthetic in 1970s-80s due to polyuric renal failure; now used only at low analgesic doses (3-6 mL)
  • Mechanism: GABA-A agonist and NMDA antagonist causing CNS depression and analgesia
  • Absolute contraindication: personal/family history of malignant hyperthermia (all volatile anesthetics trigger MH)
  • Avoid with nephrotoxic drugs (aminoglycosides, NSAIDs, tetracyclines) due to additive fluoride toxicity
  • Metabolized by CYP2E1 to inorganic fluoride, which damages renal tubules and causes nephrogenic diabetes insipidus pattern
  • Self-administered via handheld inhaler for acute trauma pain; onset 3-5 minutes, duration 15-30 minutes
  • Classic exam vignette: 1960s-70s surgery patient develops polyuria and inability to concentrate urine post-anesthesia

Indications

Methoxyflurane at low analgesic doses is indicated for:

  • Acute trauma pain: Prehospital and emergency department management of moderate to severe pain from musculoskeletal injuries, burns, and trauma
  • Procedural analgesia: Short procedures such as wound care, dressing changes, abscess drainage, and minor surgical interventions
  • Obstetric pain: Labor analgesia in some countries (though epidural and other methods are preferred)
  • Sports injuries: On-field acute pain management

Methoxyflurane is particularly useful when intravenous access is difficult or delayed, as it can be self-administered via a handheld inhaler device. The typical duration of use is 25-30 minutes per episode, with onset of analgesia within 6-10 inhalations.

Historically, methoxyflurane was used as a general anesthetic agent but was withdrawn from anesthetic practice due to nephrotoxicity at higher cumulative doses.

Pharmacokinetics

Absorption and distribution:

  • Rapid absorption via pulmonary alveoli
  • Onset of analgesia: 6-10 inhalations (3-5 minutes)
  • Peak effect: 10-15 minutes
  • Highly lipophilic with extensive tissue distribution
  • Blood:gas partition coefficient 12-15 (high solubility, slow equilibration)

Metabolism:

  • Extensive hepatic metabolism (50-75% of absorbed dose)
  • Primary enzyme: CYP2E1
  • Metabolites: inorganic fluoride, dichloroacetic acid, methoxydifluoroacetic acid
  • Peak serum fluoride levels typically occur 30-60 minutes post-exposure, aligning with the rapid absorption kinetics of inhaled agents and the onset of clinical effects

Elimination:

  • Renal excretion of fluoride metabolites (can persist for days)
  • Pulmonary elimination of unchanged drug (25-50%)
  • Terminal half-life: 15-30 hours (prolonged due to tissue redistribution)
  • Duration of analgesic effect: 15-30 minutes after cessation of inhalation

Special populations:

  • Renal impairment: Avoid or use with extreme caution due to fluoride accumulation
  • Hepatic impairment: Reduced metabolism may alter drug effects
  • Elderly: May have increased sensitivity and prolonged effects

Adverse effects

Common (>1%)

  • Dizziness, drowsiness, and lightheadedness
  • Headache
  • Nausea (5-10% of patients)
  • Cough or throat irritation
  • Taste disturbance
  • Euphoria or dissociative feelings

Serious

Nephrotoxicity (dose-dependent):

  • High-output polyuric renal failure from fluoride-induced tubular damage
  • Nephrotoxicity risk correlates with serum fluoride levels >50 μmol/L; cumulative doses >15 mL historically produced such levels during anesthetic use
  • At low analgesic doses (3-6 mL), fluoride levels remain well below the toxic threshold (typically 15-30 μmol/L), making nephrotoxicity risk minimal
  • Mechanism: Direct toxicity to renal tubular cells, particularly the proximal tubule and loop of Henle
  • May manifest as nephrogenic diabetes insipidus, decreased concentrating ability, elevated creatinine

Hepatotoxicity:

  • Rare hepatitis or hepatic dysfunction
  • Transient elevation of liver enzymes

Central nervous system:

  • Excessive sedation or loss of consciousness (with overdose or prolonged use)
  • Respiratory depression (rare at analgesic doses)
  • Seizures (very rare)

Malignant hyperthermia:

  • Rare but life-threatening hypermetabolic crisis in genetically susceptible individuals
  • Triggered in patients with mutations in RYR1 or CACNA1S genes

Other considerations

  • Chronic exposure (occupational) may cause peripheral neuropathy
  • Theoretical teratogenic effects (avoid in pregnancy)
  • Environmental impact: potent greenhouse gas (global warming potential)

Contraindications and warnings

Absolute contraindications

  • Known or suspected personal or family history of malignant hyperthermia
  • Hypersensitivity to methoxyflurane or other halogenated anesthetics
  • Pre-existing renal impairment or chronic kidney disease
  • Cardiovascular instability or severe cardiac disease
  • Altered consciousness or inability to self-administer safely
  • Clinically significant hepatic impairment

Relative contraindications and warnings

  • Concurrent nephrotoxic drugs: Aminoglycosides, NSAIDs, tetracyclines increase fluoride toxicity risk
  • Enzyme inducers: Drugs inducing CYP2E1 (isoniazid, ethanol) may increase fluoride production
  • Pregnancy: Avoid use, especially in first trimester (limited safety data)
  • Breastfeeding: Methoxyflurane and metabolites may be excreted in breast milk
  • Pediatric use: Safety in children <18 years varies by region; some countries approve use in children with supervision
  • Repeated or prolonged use: Cumulative exposure increases nephrotoxicity risk; limit total lifetime exposure
  • Occupational exposure: Healthcare workers should minimize environmental exposure

Monitoring

  • For analgesic use, no routine monitoring required
  • If cumulative exposure approaches 15 mL or multiple administrations occur, consider serum fluoride levels and renal function testing
  • Patients with risk factors for renal toxicity should be monitored for changes in urine output and creatinine

Drug interactions

Pharmacodynamic interactions

CNS depressants (additive sedation):

  • Opioids, benzodiazepines, barbiturates
  • Alcohol
  • Antihistamines, antipsychotics
  • Risk of excessive sedation and respiratory depression

Nephrotoxic agents (increased fluoride toxicity risk):

  • Aminoglycoside antibiotics (gentamicin, tobramycin)
  • NSAIDs (especially with chronic use)
  • Tetracyclines
  • Amphotericin B, cyclosporine, tacrolimus
  • Avoid concurrent use or minimize methoxyflurane exposure

Pharmacokinetic interactions

CYP2E1 inducers (increased fluoride production):

  • Chronic ethanol consumption
  • Isoniazid
  • May increase metabolism to toxic fluoride metabolites

CYP2E1 inhibitors (decreased metabolism):

  • Disulfiram
  • May reduce fluoride production but prolong anesthetic effects

Other considerations

  • Succinylcholine and other muscle relaxants: Theoretical interaction risk in context of general anesthesia (not relevant at analgesic doses)
  • Other volatile anesthetics: Avoid concurrent use
  • Vasopressors: Halogenated anesthetics may sensitize myocardium to catecholamines, increasing arrhythmia risk (less relevant at low analgesic doses)

Clinical pearls

  • Historical context: Methoxyflurane was widely used as a general anesthetic in the 1960s-70s but was withdrawn after recognition of dose-dependent nephrotoxicity. The key teaching point is that cumulative dose determines renal toxicity risk—low-dose analgesic use (3-6 mL) has an excellent safety profile.
  • Self-administration advantage: The handheld Penthrox inhaler allows patient-controlled analgesia without IV access, making it ideal for prehospital trauma care, austere environments, and emergency departments with high patient volumes.
  • Fluoride toxicity threshold: Serum fluoride levels >50 μmol/L are associated with nephrotoxicity. Analgesic doses typically produce peak levels of 15-30 μmol/L, well below this threshold. Cumulative lifetime exposure should not exceed 15 mL total.
  • Malignant hyperthermia trigger: Methoxyflurane is a known trigger for malignant hyperthermia in susceptible individuals. Screen for personal or family history before use. Treatment is immediate dantrolene administration.
  • Exam association: The classic USMLE/PLAB scenario involves a patient who received methoxyflurane anesthesia in the 1960s-70s and subsequently developed high-output renal failure with polyuria and inability to concentrate urine (nephrogenic diabetes insipidus pattern). Look for mention of fluoride ions in the answer choices.
  • Environmental concern: Methoxyflurane has a global warming potential approximately 20 times that of sevoflurane, raising environmental sustainability questions about its use.
  • Rapid onset, short duration: Analgesia begins within 3-5 minutes and lasts 15-30 minutes after stopping inhalation, making it well-suited for brief painful procedures.
  • Not a controlled substance: Unlike opioids, methoxyflurane is not a scheduled drug, simplifying logistics in emergency care settings.
  • Contraindication memory aid: Think "ReMHaL" - Renal disease, Malignant Hyperthermia history, altered consciousness, Liver disease.
Mnemonic

FLUORIDE for methoxyflurane nephrotoxicity: Fluoride metabolites, Loop of Henle damage, Urine output high (polyuria), Osmolality low (can't concentrate), Renal tubule toxicity, Isoniazid increases risk, Dose-dependent effect, Elimination impaired in renal disease

Practice questions

1. A 68-year-old man undergoes elective abdominal surgery under general anesthesia with methoxyflurane in 1972. Ten days postoperatively, he develops polyuria (6 L/day), polydipsia, and fatigue. Laboratory findings show serum sodium 148 mEq/L, serum creatinine 2.8 mg/dL (baseline 1.0 mg/dL), and urine osmolality 180 mOsm/kg despite serum osmolality of 310 mOsm/kg. Urine output does not decrease with fluid restriction. Which of the following best explains this patient's condition?

Answer: A. This patient has high-output renal failure with nephrogenic diabetes insipidus caused by methoxyflurane's fluoride metabolites, which directly damage renal tubular cells and impair concentrating ability. The key findings are polyuria with dilute urine (low osmolality) despite high serum osmolality and hypernatremia, indicating the kidneys cannot respond to ADH. This was the classic adverse effect that led to methoxyflurane's withdrawal as an anesthetic. SIADH would cause hyponatremia, not hypernatremia. ATN typically causes oliguria, not polyuria. The elevated creatinine and lack of response to fluid restriction rule out prerenal azotemia and primary polydipsia.

2. A 32-year-old construction worker sustains a displaced tibial fracture at a remote worksite. Emergency responders offer him a handheld methoxyflurane inhaler for pain relief during transport. The patient's medical history includes a family history of his father experiencing severe complications during routine surgery requiring emergent cooling measures and dantrolene administration. Which of the following is the most appropriate next step?

Answer: B. The father's history strongly suggests malignant hyperthermia susceptibility, which has autosomal dominant inheritance. All volatile anesthetics including methoxyflurane are absolute contraindications in patients with personal or family history of MH, regardless of dose. Prophylactic dantrolene does not prevent MH triggered by volatile agents; the only safe approach is complete avoidance. Alternative analgesics such as opioids (IV/IM), ketamine, or regional anesthesia should be used instead. Dose reduction and monitoring do not eliminate the MH trigger risk.

3. A 45-year-old woman with diabetic nephropathy (baseline creatinine 2.2 mg/dL) presents to the emergency department with a laceration requiring suturing. The physician considers using methoxyflurane for procedural analgesia. The patient is also taking gentamicin for a urinary tract infection and ibuprofen 800 mg three times daily for chronic back pain. Which of the following best explains why methoxyflurane should be avoided in this patient?

Answer: B. This patient has multiple risk factors for methoxyflurane nephrotoxicity: pre-existing renal impairment (contraindication to methoxyflurane use), concurrent gentamicin (aminoglycoside nephrotoxicity potentiates fluoride toxicity), and chronic NSAID use (additional nephrotoxic stress). Methoxyflurane is metabolized to fluoride ions that directly damage renal tubules; patients with existing kidney disease cannot safely excrete fluoride and are at extremely high risk for worsening renal failure. The combination of baseline CKD plus two nephrotoxic drugs makes methoxyflurane absolutely contraindicated. Alternative analgesics should be chosen. Methoxyflurane works quickly (3-5 minutes) and is effective for procedural pain, but safety concerns override efficacy in this scenario.

Frequently asked questions

How does methoxyflurane work as a pain reliever?

Methoxyflurane provides analgesia by enhancing GABA-A receptor activity (increasing inhibitory neurotransmission) and blocking NMDA receptors (reducing excitatory pain signals) in the central nervous system. At sub-anesthetic concentrations used for pain relief (0.1-0.3%), it depresses pain pathways without causing loss of consciousness. The drug is inhaled via a handheld device, rapidly absorbed through the lungs, and produces analgesia within 3-5 minutes that lasts 15-30 minutes after stopping inhalation.

What are the side effects of methoxyflurane?

Common side effects include dizziness, drowsiness, headache, nausea (5-10%), and throat irritation. The most serious adverse effect is dose-dependent nephrotoxicity caused by fluoride metabolites, which can result in high-output renal failure with polyuria. However, this occurs primarily with high cumulative doses (>15 mL) or prolonged anesthetic use; low-dose analgesic use (3-6 mL) has minimal nephrotoxicity risk. Methoxyflurane can also trigger malignant hyperthermia in genetically susceptible individuals, making personal or family history of MH an absolute contraindication.

Why was methoxyflurane discontinued as an anesthetic?

Methoxyflurane was withdrawn from general anesthetic use in the 1970s-1980s after discovery of dose-dependent nephrotoxicity. High cumulative doses used for anesthesia caused the drug to be metabolized into toxic levels of inorganic fluoride ions (>50 μmol/L), which directly damage renal tubular cells, particularly in the proximal tubule and loop of Henle. This resulted in high-output polyuric renal failure with inability to concentrate urine, resembling nephrogenic diabetes insipidus. Modern use is restricted to low-dose analgesic applications (3-6 mL) where fluoride levels remain safely below the toxic threshold.

Can methoxyflurane be used with other pain medications?

Methoxyflurane can be used with other analgesics but requires caution with CNS depressants like opioids and benzodiazepines due to additive sedation and respiratory depression risk. More importantly, it should be avoided with nephrotoxic drugs including aminoglycoside antibiotics, NSAIDs (especially chronic use), and tetracyclines, as these increase fluoride-related kidney toxicity. Enzyme inducers like isoniazid and chronic alcohol may increase metabolism to toxic fluoride metabolites. Always review the patient's medication list before administration, particularly checking for drugs affecting kidney function or CYP2E1 metabolism.

What is the difference between methoxyflurane and other inhaled anesthetics like sevoflurane?

Methoxyflurane differs from modern inhaled anesthetics (sevoflurane, desflurane, isoflurane) primarily in its extensive metabolism and nephrotoxicity profile. While 50-75% of methoxyflurane is metabolized to fluoride ions that can damage kidneys, modern agents undergo minimal metabolism (<5%). Methoxyflurane has a much higher blood:gas partition coefficient (12-15 vs 0.6-1.4), meaning slower induction and emergence. Currently, methoxyflurane is used only for analgesia at sub-anesthetic doses via handheld inhalers, whereas sevoflurane and others are standard general anesthetics. All volatile anesthetics share the ability to trigger malignant hyperthermia.

Conditions it is used for

Acute trauma painMusculoskeletal injuriesBurnsProcedural painWound painLabor painSports injuriesEmergency pain
SevofluraneDesfluraneIsofluraneNitrous oxideKetamineFentanylMorphineEntonox

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02BG09

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.